Literature DB >> 16304076

Quality, innovation, and value for money: NICE and the British National Health Service.

Steven D Pearson1, Michael D Rawlins.   

Abstract

The National Institute for Health and Clinical Excellence (NICE) was established as a part of the British National Health Service in 1999 to set standards for the adoption of new health care technologies and the management of specific conditions. In doing so it was required explicitly to take into account both clinical effectiveness and cost-effectiveness. This article describes how NICE has responded to the challenge and considers whether its experience of balancing quality, innovation, and value for money holds policy lessons for the United States.

Mesh:

Year:  2005        PMID: 16304076     DOI: 10.1001/jama.294.20.2618

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  36 in total

1.  Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions.

Authors:  Shelby D Reed; Yanhong Li; Shital Kamble; Daniel Polsky; Felicia L Graham; Margaret T Bowers; Gregory P Samsa; Sara Paul; Kevin A Schulman; David J Whellan; Barbara J Riegel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-12-06

2.  Common Drug Review recommendations: an evidence base for expectations?

Authors:  Angela Rocchi; Elizabeth Miller; Robert B Hopkins; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

Review 3.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Evidence, ethics and inclusion: a broader base for NICE.

Authors:  Stephen Wilmot
Journal:  Med Health Care Philos       Date:  2011-05

5.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

6.  A medical economic fairy tale: Jack, the magic beans, Medicare and the US FDA.

Authors:  Neil J Nusbaum
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  Should we abandon QALYs as a resource allocation tool?

Authors:  Sandeep Vijan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Should NICE evaluate complementary and alternative medicine?

Authors:  Linda Franck; Cyril Chantler; Michael Dixon
Journal:  BMJ       Date:  2007-03-10

10.  NICE: managing conflict.

Authors:  Steve Iliffe; Jill Manthorpe
Journal:  J R Soc Med       Date:  2008-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.